Catalyst Wire Dossier Catalyst Wire Dossier
EMA guidance · 2024-11-15

Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids

View source ↗

Summary

EMA updated guidance to minimize the risk of serious interactions between Mysimba (naltrexone/bupropion) and opioid medicines. The agency notes that using opioi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mysimba (naltrexone/bupropion)

Snippet

Use of opioid medicines with Mysimba may lead to serious side effects